1
|
Douine M, Bonifay T, Lambert Y, Mutricy L, Galindo MS, Godin A, Bourhy P, Picardeau M, Saout M, Demar M, Sanna A, Mosnier E, Blaizot R, Couppié P, Nacher M, Adenis A, Suarez-Mutis M, Vreden S, Epelboin L, Schaub R. Zoonoses and gold mining: A cross-sectional study to assess yellow fever immunization, Q fever, leptospirosis and leishmaniasis among the population working on illegal mining camps in French Guiana. PLoS Negl Trop Dis 2022; 16:e0010326. [PMID: 35969647 PMCID: PMC9410546 DOI: 10.1371/journal.pntd.0010326] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Revised: 08/25/2022] [Accepted: 06/12/2022] [Indexed: 11/28/2022] Open
Abstract
Background Most emerging pathogens are zoonoses and have a wildlife origin. Anthropization and disruption of ecosystems favor the crossing of inter-species barriers. We hypothesize that the marginalized population of undocumented goldminers in the Amazon is at risk of acquiring zoonoses. Method A multicentric cross-sectional study included consenting gold-mining adult workers in 2019. A clinical examination recorded dermatological signs of leishmaniosis and past history of yellow fever vaccination. Biological tests were performed for yellow fever, Q fever and leptospirosis serologies. Additional blood samples from a previous study in 2015 were also tested for leptospirosis. Results In 2019, 380 individuals were included in the study, along with 407 samples from the 2015 biological collection. The seroprevalence of leptospirosis was 31.0% [95%CI = 26.4–35.5] in 2015 and 28.1% [23.5–32.7] in 2019. The seroprevalence of Q fever was 2.9% [1.2–4.6]. The majority of participants reported being vaccinated against yellow fever (93.6%) and 97.9% had seroneutralizing antibodies. The prevalence of suspected active mucocutaneous leishmaniasis was 2.4% [0.8–3.9]. Discussion These unique data shed new light on the transmission cycles of zoonoses still poorly understood in the region. They support the existence of a wild cycle of leptospirosis but not of Q fever. Leishmaniasis prevalence was high because of life conditions and tree felling. High yellow fever vaccine coverage was reassuring in this endemic area. In the era of global health, special attention must be paid to these vulnerable populations in direct contact with the tropical ecosystem and away from the health care system. Many pathogens are zoonotic in origin and human transmission can occur via vector, direct contact, inhalation, absorption, among other routes enabling human-reservoir interaction. In Amazonia, the cycle of these pathogens (the reservoir, the mode of transmission …) is not always well known. It is important to better understand these cycles in order to evaluate and anticipate the potential risk for human health, both on an individual and collective scale (risk of epidemic). In French Guiana, a French territory located in the Amazon, undocumented gold miners represent several thousand people mainly from Brazil who work in very remote areas in the middle of the rainforest. Documenting several zoonotic diseases among this population living in the middle of biodiversity is very valuable to better understand these cycles but also to assess the impact for their own health and to identify risks for public health. This article provides new data for four zoonoses: Q-fever, leptospirosis, leishmaniasis and yellow fever in this population and discusses the contributions to the understanding of cycles and public health issues.
Collapse
Affiliation(s)
- Maylis Douine
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Centre de Ressources Biologiques Amazonie, Cayenne, French Guiana
- * E-mail:
| | - Timothée Bonifay
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Yann Lambert
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Louise Mutricy
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Muriel Suzanne Galindo
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Audrey Godin
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Pascale Bourhy
- National Reference Center for Leptospirosis, Biology of Spirochetes unit, Institut Pasteur, Paris, France
| | - Mathieu Picardeau
- National Reference Center for Leptospirosis, Biology of Spirochetes unit, Institut Pasteur, Paris, France
| | - Mona Saout
- TBIP, Université de la Guyane, Cayenne, French Guiana
| | - Magalie Demar
- TBIP, Université de la Guyane, Cayenne, French Guiana
- University Laboratory of Mycology-Parasitology, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Alice Sanna
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Emilie Mosnier
- Delocalized Health Centers, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Romain Blaizot
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Department of Dermatology, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Pierre Couppié
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Department of Dermatology, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Mathieu Nacher
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Centre de Ressources Biologiques Amazonie, Cayenne, French Guiana
| | - Antoine Adenis
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Centre de Ressources Biologiques Amazonie, Cayenne, French Guiana
| | - Martha Suarez-Mutis
- Laboratory of Parasitic Diseases, Institute Oswaldo Cruz/Fiocruz, Rio de Janeiro, Brazil
| | - Stephen Vreden
- Foundation for Scientific Research Suriname, Paramaribo, Suriname
| | - Loïc Epelboin
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
- TBIP, Université de la Guyane, Cayenne, French Guiana
- Infectious and Tropical Diseases Unit, Centre Hospitalier de Cayenne, Cayenne, French Guiana
| | - Roxane Schaub
- Centre d’Investigation Clinique Antilles-Guyane (Inserm 1424), Centre Hospitalier de Cayenne, Cayenne, French Guiana
- TBIP, Université de la Guyane, Cayenne, French Guiana
| |
Collapse
|
2
|
Nacher M, Mergeay-Fabre M, Blanchet D, Benois O, Pozl T, Mesphoule P, Sainte-Rose V, Vialette V, Toulet B, Moua A, Saout M, Simon S, Guidarelli M, Galindo M, Biche B, Faurous W, Chaizemartin L, Fahrasmane A, Rochemont D, Diop F, Niang M, Pujo J, Vignier N, Dotou D, Vabret A, Demar M. Diagnostic accuracy and acceptability of molecular diagnosis of COVID-19 on saliva samples relative to nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The COVISAL study. PLoS One 2021; 16:e0257169. [PMID: 34516569 PMCID: PMC8437265 DOI: 10.1371/journal.pone.0257169] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Accepted: 08/24/2021] [Indexed: 12/23/2022] Open
Abstract
A prospective study was conducted among different intra and extra-hospital populations of French Guiana to evaluate the performance of saliva testing compared to nasopharyngeal swabs. Persons aged 3 years and older with mild symptoms suggestive of COVID-19 and asymptomatic persons with a testing indication were prospectively enrolled. Nasopharyngeal and salivary samples were stored at 4°C before analysis. Both samples were analyzed with the same Real-time PCR amplification of E gene, N gene, and RdRp gene. Between July 22th and October 28th, 1159 persons were included, of which 1028 were analyzed. When only considering as positives those with 2 target genes with Ct values <35, the sensitivity of RT-PCR on saliva samples was 100% relative to nasopharyngeal samples. Specificity positive and negative predictive values were above 90%. Across a variety of cultures and socioeconomic conditions, saliva tests were generally much preferred to nasopharyngeal tests and persons seemed largely confident that they could self-sample. For positive patients defined as those with the amplification of 2 specific target genes with Ct values below 35, the sensitivity and specificity of RT-PCR on saliva samples was similar to nasopharyngeal samples despite the broad range of challenging circumstances in a tropical environment.
Collapse
Affiliation(s)
- Mathieu Nacher
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
- DFR Santé, Université de Guyane, Cayenne, French Guiana
- * E-mail:
| | - Mayka Mergeay-Fabre
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Denis Blanchet
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Orelie Benois
- Centre de Ressources Biologiques (CRB) Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Tristan Pozl
- Centre de Ressources Biologiques (CRB) Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Pauline Mesphoule
- Centre de Ressources Biologiques (CRB) Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Vincent Sainte-Rose
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Véronique Vialette
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Bruno Toulet
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Aurélie Moua
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Mona Saout
- Unité mixte de recherche TBIP, Université de Guyane, Cayenne, French Guiana
| | - Stéphane Simon
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Manon Guidarelli
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Muriel Galindo
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Barbara Biche
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - William Faurous
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Laurie Chaizemartin
- Centre délocalisé de prévention et soins de Maripasoula, Maripasoula, French Guiana
| | - Aniza Fahrasmane
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Devi Rochemont
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Fode Diop
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Moussa Niang
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Jean Pujo
- Service des Urgences, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Nicolas Vignier
- CIC INSERM 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Dominique Dotou
- Service de Gynécologie Obstétrique, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | | | - Magalie Demar
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
- Unité mixte de recherche TBIP, Université de Guyane, Cayenne, French Guiana
| |
Collapse
|
3
|
Nacher M, Mergeay-Fabre M, Blanchet D, Benoit O, Pozl T, Mesphoule P, Sainte-Rose V, Vialette V, Toulet B, Moua A, Saout M, Simon S, Guidarelli M, Galindo M, Biche B, Faurous W, Chaizemartin L, Fahrasmane A, Rochemont D, Vignier N, Vabret A, Demar M. Prospective Comparison of Saliva and Nasopharyngeal Swab Sampling for Mass Screening for COVID-19. Front Med (Lausanne) 2021; 8:621160. [PMID: 33708779 PMCID: PMC7940378 DOI: 10.3389/fmed.2021.621160] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2020] [Accepted: 02/03/2021] [Indexed: 12/12/2022] Open
Abstract
Current testing for COVID-19 relies on reverse-transcriptase polymerase chain reaction from a nasopharyngeal swab specimen. Saliva samples have advantages regarding ease and painlessness of collection, which does not require trained staff and may allow self-sampling. We enrolled 776 persons at various field-testing sites and collected nasopharyngeal and pooled saliva samples. One hundred sixty two had a positive COVID-19 RT-PCR, 61% were mildly symptomatic and 39% asymptomatic. The sensitivity of RT-PCR on saliva samples vs. nasopharygeal swabs varied depending on the patient groups considered or on Ct thresholds. There were 10 (6.2%) patients with a positive saliva sample and a negative nasopharyngeal swab, all of whom had Ct values <25 for three genes. For symptomatic patients for whom the interval between symptoms onset and sampling was <10 days sensitivity was 77% but when excluding persons with isolated N gene positivity (54/162), sensitivity was 90%. In asymptomatic patients, the sensitivity was only 24%. When we looked at patients with Cts <30, sensitivity was 83 or 88.9% when considering two genes. The relatively good performance for patients with low Cts suggests that Saliva testing could be a useful and acceptable tool to identify infectious persons in mass screening contexts, a strategically important task for contact tracing and isolation in the community.
Collapse
Affiliation(s)
- Mathieu Nacher
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana.,Département Formation Recherche (DFR) Santé, Université de Guyane, Cayenne, French Guiana
| | - Mayka Mergeay-Fabre
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Denis Blanchet
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Orelie Benoit
- Centre de Ressources Biologiques Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Tristan Pozl
- Centre de Ressources Biologiques Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Pauline Mesphoule
- Centre de Ressources Biologiques Amazonie, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Vincent Sainte-Rose
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Véronique Vialette
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Bruno Toulet
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Aurélie Moua
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Mona Saout
- Unité Mixte de Recherche Tropical Biome and Immuno-Pathology (TBIP), Université de Guyane, Cayenne, French Guiana
| | - Stéphane Simon
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Manon Guidarelli
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Muriel Galindo
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Barbara Biche
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - William Faurous
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Laurie Chaizemartin
- Centre Délocalisé de Prévention et Soins de Maripasoula, Maripasoula, French Guiana
| | - Aniza Fahrasmane
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Devi Rochemont
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | - Nicolas Vignier
- Centre d'Investigation Clinique (CIC) Institut National de la Santé et de la Recherche Médicale (INSERM) 1424, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana
| | | | - Magalie Demar
- Laboratoire, Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, French Guiana.,Unité Mixte de Recherche Tropical Biome and Immuno-Pathology (TBIP), Université de Guyane, Cayenne, French Guiana
| |
Collapse
|
4
|
Flamand C, Bailly S, Fritzell C, Fernandes Pellerin S, Toure A, Chateau N, Saout M, Linares S, Dubois F, Filleul L, Kazanji M. Vaccination coverage in the context of the emerging Yellow Fever threat in French Guiana. PLoS Negl Trop Dis 2019; 13:e0007661. [PMID: 31425507 PMCID: PMC6715233 DOI: 10.1371/journal.pntd.0007661] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 08/29/2019] [Accepted: 07/24/2019] [Indexed: 12/18/2022] Open
Abstract
Background French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for yellow fever (YF). In the context of the emergent threat of YF in Latin America, we conducted a large household cross-sectional survey from June to October 2017 to estimate vaccination coverage in the population and to determine associations with sociodemographic and geographical characteristics. Methodology/Principal findings In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4–96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged populations with low socioeconomic indexes. Conclusions/Significance Despite the good vaccination coverage against YF in the general population of French Guiana resulting from the compulsory nature of YF vaccination for residents and travelers, there is an urgent need to improve vaccination coverage in vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations. Yellow fever (YF) is the most severe arbovirus to circulate in the Americas. French Guiana, a French overseas department located in South America between Brazil and Surinam, is the only European territory geographically located in the Amazonian forest complex and is considered endemic for YF. We conducted a large general population survey from June to October 2017 to estimate vaccination coverage in the population and to identify target vulnerable populations for catch-up vaccination strategies. In total, 1,415 households and 2,697 individuals were included from the 22 municipalities of French Guiana. YF vaccination coverage was estimated at 95.0% (95% CI: 93.4–96.2) in the entire territory but was spatially heterogeneous, with the lowest levels estimated in the western part of the territory along the Surinamese cross-border region, particularly in children under 16 years who were not enrolled in school, immigrant adults and disadvantaged groups of populations with low socioeconomic indexes. Our findings showed that vaccination campaigns should be prioritized and adapted to improve vaccination coverage among vulnerable populations living in the northwestern part of the territory to limit the risk of transmission in the context of the emerging YF threat in South America. Despite the relative rarity of YF and the significant number of infectious and tropical diseases in French Guiana, clinicians should adopt a high index of suspicion for YF, particularly in vulnerable and at-risk populations.
Collapse
Affiliation(s)
- Claude Flamand
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
- * E-mail:
| | - Sarah Bailly
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Camille Fritzell
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | | | - Alhassane Toure
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Naïssa Chateau
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Mona Saout
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| | - Sébastien Linares
- Geographic Information and Knowledge Dissemination Unit, Direction de l’Environnement, de l’Aménagement et du logement Guyane, Cayenne, French Guiana
| | - Fabien Dubois
- Geographic Information and Knowledge Dissemination Unit, Direction de l’Environnement, de l’Aménagement et du logement Guyane, Cayenne, French Guiana
| | | | - Mirdad Kazanji
- Epidemiology Unit, Institut Pasteur in French Guiana, Cayenne, French Guiana
| |
Collapse
|
5
|
Leba LJ, Brunschwig C, Saout M, Martial K, Vulcain E, Bereau D, Robinson JC. Optimization of a DNA nicking assay to evaluate Oenocarpus bataua and Camellia sinensis antioxidant capacity. Int J Mol Sci 2014; 15:18023-39. [PMID: 25302614 PMCID: PMC4227202 DOI: 10.3390/ijms151018023] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 09/18/2014] [Accepted: 09/25/2014] [Indexed: 11/16/2022] Open
Abstract
This study was aimed at assessing the DNA damage protective activity of different types of extracts (aqueous, methanolic and acetonic) using an in vitro DNA nicking assay. Several parameters were optimized using the pUC18 plasmid, especially FeSO4, EDTA, solvent concentrations and incubation time. Special attention has been paid to removing the protective and damaging effect of the solvent and FeSO4 respectively, as well as to identifying the relevant positive and negative controls. For each solvent, the optimal conditions were determined: (i) for aqueous extracts, 0.33 mM of FeSO4 and 0.62 mM of EDTA were incubated for 20 min at 37 °C; (ii) for acetone extracts, 1.16% solvent were incubated for 15 min at 37 °C with 1.3 mM of FeSO4 and 2.5 mM of EDTA and (iii) for methanol extracts, 0.16% solvent, were incubated for 1.5 h at 37 °C with 0.33 mM of FeSO4 and 0.62 mM of EDTA. Using the optimized conditions, the DNA damage protective activity of aqueous, methanolic and acetonic extracts of an Amazonian palm berry (Oenocarpus bataua) and green tea (Camellia sinensis) was assessed. Aqueous and acetonic Oenocarpus bataua extracts were protective against DNA damage, whereas aqueous, methanolic and acetonic extracts of Camellia sinensis extracts induced DNA damage.
Collapse
Affiliation(s)
- Louis-Jérôme Leba
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Christel Brunschwig
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Mona Saout
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Karine Martial
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Emmanuelle Vulcain
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Didier Bereau
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| | - Jean-Charles Robinson
- Université des Antilles et de la Guyane, UMR QUALITROP, campus universitaire de Troubiran, P.O. Box 792, 97337 Cayenne Cedex, French Guiana, France.
| |
Collapse
|